ERBB2 and prostate carcinoma: In summary, our multimarker analysis provides evidence that EGFR, Her-2 and ErbB3 are involved in the constitutive activation of Akt and NF-κB, which validates, for the first time in prostate cancer samples, previous in vitro data obtained in cell lines.